Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
- UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals June 9, 2026
- BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap June 9, 2026
Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by Max61Cu-NU101 is a new PSMA-targeted PET/SPECT tracer for prostate cancer that showed promise in phase 1, detecting more lesions than 18F-piflufolastat (Pylarify) in half of the 8 patients studied, with lower background uptake and no side effects. The key advantage is its 3.3-hour half-life, compared to 68 minutes for 68Ga-PSMA-11 and 109 minutes for 18F-piflufolastat. […]
UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals
/in Clinical Trial, Metastatic, Phase 1/by MaxProstate cancer can become harder to treat when it changes from the usual adenocarcinoma form into neuroendocrine prostate cancer, or NEPC. A recent study suggests that this transition may begin earlier than expected, during an intermediate phase when the cells are still partly prostate-like but are already starting to acquire neuroendocrine features. A central finding […]
BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap
/in Observational, Retrospective studies/by MaxRecent real-world data clarify how homologous recombination repair (HRR) alterations, especially BRCA1/2 mutations, affect outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with androgen receptor pathway inhibitors (ARPIs). In a US cohort of 745 patients, overall differences in time-to-next-treatment (TTNT) and time-to-castration resistance (TTCR) were modest between patients without HRR alterations and those with non-BRCA […]
Ultrasound-Driven Cavitation Reprograms Drug Response and Immune Sensitivity in Neuroendocrine Prostate Cancer
/in Preclinical Research/by MaxAcoustic cavitation is emerging as a surprisingly powerful tool in the therapeutic landscape of neuroendocrine prostate cancer (NEPC), a disease state notoriously resistant to conventional treatments. By combining nanometer-scale lipid microbubbles with targeted ultrasound, researchers are leveraging a physical mechanism to overcome some of the most entrenched biological barriers in aggressive prostate cancer. At its […]
Confirmed Efficacy of Rucaparib in BRCA-Mutated mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxRucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]
Real-World OPTYX Study: Sustained Castration and Rapid Testosterone Recovery with Relugolix
/in Observational/by MaxRelugolix (Orgovyx), the first oral androgen deprivation therapy approved for advanced prostate cancer, continues to show consistent performance in real-world settings. New data from the OPTYX study, a prospective observational analysis, provide further evidence on testosterone suppression, recovery, and PSA control in routine clinical practice. The study included 999 patients, predominantly with nonmetastatic disease and […]
Tipifarnib Shows Early Promise as an Adjuvant in Enzalutamide-Resistant Prostate Cancer
/in Preclinical Research/by MaxTipifarnib is an interesting repurposing candidate in advanced prostate cancer because it may interfere with a resistance mechanism that goes beyond androgen signaling alone. In a preclinical work presented during the AUA 2026 meeting, the drug reduced exosome release from aggressive castration-resistant prostate cancer cells, including 22Rv1 and CWR-R1, by about 30% at low dose, […]
ZNF281 Emerges as a Novel Driver and Therapeutic Target in Advanced Prostate Cancer
/in Preclinical Research/by MaxZNF281 is a Krüppel-type zinc-finger transcription factor previously implicated in cancer stemness, but its role in prostate cancer has remained largely unexplored. In a new study, researchers evaluated ZNF281 expression across human prostate cancer samples, including primary tumors, metastatic lymph nodes, and normal prostate tissue. The findings revealed significantly higher expression of ZNF281 in metastatic […]